IBSA Reacquires Commercial Rights to the Flector® Brand in the US
IBSA Reacquires Commercial Rights to the Flector® Brand in the US Developer of Flector Adds to Portfolio of Topical Pain Therapies News provided by Share this article Share this article PARSIPPANY, N.J., Jan. 12, 2021 /PRNewswire/ -- IBSA Pharma Inc. has taken back marketing and distribution rights for Flector (diclofenac epolamine) topical system 1.3% from Pfizer as of January 1 st, 2021. With the return of the commercial rights of Flector, a product that IBSA has developed, IBSA now offers two prescription topical drugs to treat acute pain due to minor strains, sprains, and contusions. Bo...
Source: prnewswire.com